Skip to main content
SpringerLink
Log in

Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphomas

  • Chapter
  • First Online:
Book cover T-Cell Lymphomas

Part of the book series: Contemporary Hematology ((CH))

  • 1233 Accesses

Abstract

Peripheral T-cell Lymphoma (PTCL) is a heterogeneous group of lymphomas with variable histology, immuno-phenotype features, geographic and ethnic distribution, and clinical natural history. No standard treatment exists for this group of diseases. Therefore, the usual frontline treatment derives from the one primarily used for the larger group of aggressive B-cell lymphomas, with generally worse results. Given the poor outcomes with the current therapy, high-dose chemotherapy and autologous and allogeneic stem cell transplantation are being used with increased frequency, both in the up-front and salvage settings, with varying result rates. Although there are no published randomized studies at present, preliminary information from the first retrospective studies and more recently from prospective studies indicates that the poor outcome currently attributed to these malignancies may change with the implementation of these therapeutic modalities. In addition, better results are expected once new active and specific agents are incorporated into the induction part of the therapeutic strategy, making consolidation with these high-dose intensification procedures available to more patients, as they receive the transplant after a meaningful response to induction therapy. Although experience with allogeneic stem cell transplantation is sparse, preliminary information suggests the existence of a graft-vs.-T-cell lymphoma effect. In this chapter, we review the available experience with autologous and allogeneic stem cell transplantation in PTCL in both up-front and salvage settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC press; 2008.

    Google Scholar 

  2. Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol. 2004;15(10):1447–9.

    Article  PubMed  CAS  Google Scholar 

  3. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1987;316(24):1493–8.

    Article  PubMed  CAS  Google Scholar 

  4. Rodriguez J, Conde E, Gutierrez A, Lahuerta JJ, Arranz R, Sureda A, et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica. 2007;92(8):1067–74.

    Article  PubMed  Google Scholar 

  5. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18(4):652–7.

    Article  PubMed  CAS  Google Scholar 

  6. Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40(5):443–50.

    Article  PubMed  CAS  Google Scholar 

  7. Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33(4):405–10.

    Article  PubMed  CAS  Google Scholar 

  8. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20(10):2472–9.

    Article  PubMed  CAS  Google Scholar 

  9. Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106–13.

    Article  PubMed  CAS  Google Scholar 

  10. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533–8.

    Article  PubMed  CAS  Google Scholar 

  11. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007;79:32–8.

    Article  PubMed  Google Scholar 

  12. d’Amore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st Line treatment in peripheral T-cell lymphomas (PTCL)—a phase II study of the Nordic lymphoma group (NLG). Blood. 2006;108:401a.

    Article  Google Scholar 

  13. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19:958–63.

    Article  PubMed  CAS  Google Scholar 

  14. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(2):218–24.

    PubMed  CAS  Google Scholar 

  15. Hashimoto H, Sawada K, Koizumi K, Nishio M, Endo T, Takashima T, et al. Effective CD34+ selected autologous peripheral blood stem cell transplantation in a patient with subcutaneous panniculitic T cell lymphoma (SPTCL) transformed into leukemia. Bone Marrow Transplant. 1999;24(12):1369–71.

    Article  PubMed  CAS  Google Scholar 

  16. Nishio M, Koizumi K, Endo T, Takashima H, Haseyama Y, Fujimoto K, et al. Effective high-dose chemotherapy combined with CD34  +  −selected autologous peripheral blood stem cell transplantation in a patient with cutaneous CD30-negative large T cell lymphoma. Bone Marrow Transplant. 2000;25(12):1315–7.

    Article  PubMed  CAS  Google Scholar 

  17. Koizumi K, Sawada K, Nishio M, Katagiri E, Fukae J, Fukada Y, et al. Effective high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. Bone Marrow Transplant. 1997;20(2):171–3.

    Article  PubMed  CAS  Google Scholar 

  18. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41(7):597–604.

    Article  PubMed  CAS  Google Scholar 

  19. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216–21.

    Article  PubMed  CAS  Google Scholar 

  20. Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14(12):1356–64.

    Article  PubMed  Google Scholar 

  21. Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol. 2003;14(11):1673–6.

    Article  PubMed  CAS  Google Scholar 

  22. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9.

    Article  PubMed  CAS  Google Scholar 

  23. van Besien KW, de Lima M, Giralt SA, Moore Jr DF, Khouri IF, Rondon G, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997;19(10):977–82.

    Article  PubMed  Google Scholar 

  24. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32(12):1159–63.

    Article  PubMed  CAS  Google Scholar 

  25. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(5):737–44.

    Article  PubMed  CAS  Google Scholar 

  26. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98(13):3595–9.

    Article  PubMed  CAS  Google Scholar 

  27. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007;21(11):2316–23.

    Article  PubMed  CAS  Google Scholar 

  28. Mollee P, Lazarus HM, Lipton J. Why aren’t we performing more allografts for aggressive non-Hodgkin’s lymphoma? Bone Marrow Transplant. 2003;31(11):953–60.

    Article  PubMed  CAS  Google Scholar 

  29. Dhedin N, Giraudier S, Gaulard P, Esperou H, Ifrah N, Michallet M, et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin’s lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol. 1999;107(1):154–61.

    Article  PubMed  CAS  Google Scholar 

  30. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131(2):223–30.

    Article  PubMed  Google Scholar 

  31. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood. 1998;92(1):76–82.

    PubMed  CAS  Google Scholar 

  32. Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14(12):1768–75.

    Article  PubMed  CAS  Google Scholar 

  33. Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120(6):978–85.

    Article  PubMed  Google Scholar 

  34. Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood. 2006;108(1):382–9.

    Article  PubMed  CAS  Google Scholar 

  35. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26(14):2264–71.

    Article  PubMed  Google Scholar 

  36. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006;20(10):1661–72.

    Article  PubMed  CAS  Google Scholar 

  37. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22(11):2172–6.

    Article  PubMed  Google Scholar 

  38. Corradini P, Dodero A, Lambertenghi-Deliliers G, Onida F. Allogeneic transplantation for peripheral and cutaneous T-cell lymphomas. Hematol Meet Rep. 2009;3:139–40.

    Google Scholar 

  39. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, et al. Allogeneic stem cell transplantation following a reduced-intensity conditioning in relapsed lymphomas: 5-year follow-up of a phase II study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant. 2009;43:S64.

    Google Scholar 

  40. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27(24):3951–8.

    Article  PubMed  Google Scholar 

  41. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110(7):2316–23.

    Article  PubMed  CAS  Google Scholar 

  42. Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2005;36(3):271–3.

    Article  PubMed  CAS  Google Scholar 

  43. Molina A, Zain J, Arber DA, Angelopolou M, O’Donnell M, Murata-Collins J, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005;23(25):6163–71.

    Article  PubMed  Google Scholar 

  44. Onida F, Saporiti G, Berti E, DellaVolpe A, Annaloro C, Usardi P, et al. Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2007;39:S40.

    Google Scholar 

  45. Gutierrez A, Caballero MD, Perez-Manga G, et al. Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant. 2008;42(12):773–81.

    Article  PubMed  CAS  Google Scholar 

  46. Rodríguez J, Conde E, Gutiérrez A, et al. The adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Hematologica. 2007;92(8):1067–74.

    Article  Google Scholar 

  47. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF. Impact of high dose chemotherapy in Peripherals T cell lymphoma. J Clin Oncol. 2001;19(17):3766–70.

    Article  PubMed  CAS  Google Scholar 

  48. Blystad AK, Enblad G, Kvaløy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001;27(7):711–6.

    Article  PubMed  CAS  Google Scholar 

  49. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S, Nimer SD, Moskowitz CH. Autologous transplantation for relapsed or primary refractory peripheral T cell lymphoma. Br J Haematol. 2006;134(2):202–7. Epub 2006 Jun 6.

    Article  PubMed  CAS  Google Scholar 

  50. Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, Sobecks R, Andresen S, Hsi ED, Pohlman B, Sweetenham JW. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow transplant 2007; 40(3):239–43.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hospital Universitario Severo Ochoa, Avenida Orellana, S/N, 28911, Leganés, Spain

    José Rodríguez

  2. Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy

    Paolo Corradini

Authors
  1. José Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Corradini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Rodríguez .

Editor information

Editors and Affiliations

  1. Yale University School of Medicine, Dept. of Medical Oncology/Hematology, Cedar Street 333, New Haven, 06520, Connecticut, USA

    Francine Foss

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rodríguez, J., Corradini, P. (2013). Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphomas. In: Foss, F. (eds) T-Cell Lymphomas. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-170-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-170-7_13

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-169-1

  • Online ISBN: 978-1-62703-170-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation